UCB Acquires Handl Therapeutics to Augment its Gene Therapy Portfolio
Shots: The acquisition will bolster UCB’s pipeline program, capabilities, and platforms in the gene therapy space. The Handl Therapeutics will continue to be based in Leuven, Belgium while working closely with UCB’s international research teams In addition, the UCB collaborated with Lacerta to focus on CNS diseases, under which Lacera will lead research, preclinical activities, …
UCB Acquires Handl Therapeutics to Augment its Gene Therapy Portfolio Read More »